Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury Christopher R Heery, Claudia Palena, Sheri McMahon, Renee N Donahue, Lauren M Lepone, Italia Grenga, Ulrike Dirmeier, Lisa Cordes, Jennifer L Marte, William Dahut, Harpreet Singh, Ravi A. Madan, Romaine I. Fernando, Duane H. Hamilton, Jeffrey Schlom and James L Gulley Clin Cancer Res August 30 2017 DOI: 10.1158/1078-0432.CCR-17-1087
Between Jan 31, 2013, and Oct 8, 2014, 53 patients were enrolled (four patients at 1 mg/kg, 13 at 3 mg/kg, 15 at 10 mg/kg, and 21 at 20 mg/kg). 18 patients were analysed in the dose-limiting toxicity analysis set: three at dose level 1 (1 mg/kg), three at dose level 2 (3 mg/kg), six at dose level 3 (10 mg/kg), and six at dose level 4 (20 mg/kg). Only one dose-limiting toxicity occurred, at the 20 mg/kg dose, and thus the maximum tolerated dose was not reached.
Immunotherapy: On the Frontier of Cure John L. Marshall, MD: This is John Marshall, director of the Ruesch Center for the Cure of Gastrointestinal (GI) Cancers at Georgetown's Lombardi Comprehensive Cancer Center in Washington, DC. Welcome to the 2014 Ruesch Center Symposium, "Fighting a Smarter War Against Cancer." Every year we try to bring together thought leaders to challenge the barriers that are keeping us from reaching our goal of curing cancer. That is what our patients want.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
